Saxenda History and Development: How Liraglutide 3 mg Went from Diabetes Drug to FDA-Approved Weight Loss Injection

From Gila Monster Venom to a Synthetic Hormone: The GLP-1 Story

The development of Saxenda traces back to the discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone first characterized in the mid-1980s by researchers including Jens Juul Holst at the University of Copenhagen. Native GLP-1 lowers blood glucose by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. The problem: endogenous GLP-1 has a plasma half-life of roughly 2 minutes, degraded almost instantly by dipeptidyl peptidase-4 (DPP-4) [1].

Early Incretin Research

The incretin effect itself was described in the 1960s, when scientists observed that oral glucose produced a larger insulin response than intravenous glucose at matched blood sugar levels. This observation pointed toward gut-derived hormones that amplified pancreatic beta-cell function. GLP-1 emerged as the dominant incretin candidate after its isolation from proglucagon gene products in 1983 [2].

Engineering a Longer-Lasting Molecule

Novo Nordisk set out to create a GLP-1 analog resistant to DPP-4 degradation. Liraglutide was engineered by attaching a C-16 fatty acid (palmitic acid) side chain to the lysine at position 26 of the GLP-1(7-37) sequence, along with a single amino acid substitution (Arg34). This acylation allows the molecule to bind non-covalently to albumin in the bloodstream, extending its half-life to approximately 13 hours and enabling once-daily dosing [3]. Liraglutide shares 97% amino acid sequence homology with native human GLP-1.

Victoza: The Diabetes Prelude That Revealed a Weight Signal

Before Saxenda existed, liraglutide entered clinical practice as Victoza at doses up to 1.8 mg daily for type 2 diabetes. The LEAD (Liraglutide Effect and Action in Diabetes) trial program, spanning six phase 3 studies from 2007 to 2009, established glycemic efficacy. But the weight data caught attention.

Weight Loss in the LEAD Trials

Across the LEAD program, patients on liraglutide 1.8 mg lost 2 to 3 kg more than those on comparator therapies including glimepiride, rosiglitazone, and insulin glargine [4]. This was notable because most diabetes drugs at the time caused weight gain. The FDA approved Victoza on January 25, 2010, for glycemic control in type 2 diabetes.

A Deliberate Pivot Toward Obesity

Novo Nordisk did not stumble into obesity pharmacology. The company had already marketed orlistat under license and understood the commercial field. The consistent weight reduction signal from LEAD, combined with growing epidemiological urgency (adult obesity prevalence in the U.S. Had crossed 35% by 2012), prompted a dose-ranging study. A 20-week phase 2 trial published in The Lancet in 2009 (N=564) tested liraglutide at 1.2, 1.8, 2.4, and 3.0 mg daily against placebo and orlistat 120 mg TID. The 3.0 mg group lost 7.2 kg compared with 2.8 kg for placebo, establishing the dose that would become Saxenda [5].

The SCALE Trial Program: Building the Obesity Evidence Base

The FDA required a dedicated phase 3 program for the obesity indication. Novo Nordisk designed SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence), a four-trial suite enrolling over 5,000 participants across multiple populations.

SCALE Obesity and Prediabetes

This was the key registration trial. Published in the New England Journal of Medicine in July 2015, it randomized 3,731 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) to liraglutide 3.0 mg or placebo for 56 weeks, both with lifestyle counseling. Results: liraglutide-treated patients achieved 8.0% mean body weight loss versus 2.6% with placebo. A total of 63.2% of the liraglutide group lost ≥5% body weight, compared with 27.1% on placebo [6].

The trial also reported that 3.0 mg liraglutide reduced the cumulative incidence of type 2 diabetes by 79% over the 56-week treatment period among participants with prediabetes at baseline, a finding the investigators called "a meaningful preventive benefit beyond weight reduction alone."

SCALE Diabetes

This study focused on adults with type 2 diabetes and obesity (N=846). At 56 weeks, the 3.0 mg group lost 6.0% of body weight versus 2.0% for placebo, with a concurrent HbA1c reduction of 1.3 percentage points [7]. The smaller absolute weight loss compared to SCALE Obesity and Prediabetes reflected a pattern seen across GLP-1 trials: patients with type 2 diabetes tend to lose less weight than those without diabetes on the same agent.

SCALE Maintenance and SCALE Sleep Apnea

SCALE Maintenance (N=422) tested whether liraglutide 3.0 mg could sustain weight already lost through a low-calorie diet. Over 56 weeks, participants on liraglutide lost an additional 6.2% body weight versus 0.2% regain in the placebo arm [8]. SCALE Sleep Apnea (N=359) demonstrated a 12.2-event-per-hour reduction in the apnea-hypopnea index with liraglutide versus 6.1 with placebo at 32 weeks, showing functional respiratory benefit tied to the weight loss [9].

FDA Approval and Regulatory Milestones

The FDA approved Saxenda (liraglutide 3.0 mg) on December 23, 2014, for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The approval came with a requirement for a cardiovascular outcomes trial post-marketing, a reflection of lingering caution after the fenfluramine/dexfenfluramine withdrawals of the late 1990s [10].

The 12-Week Stopping Rule

The FDA label included a practical instruction: discontinue Saxenda if a patient has not lost at least 4% of baseline body weight by 16 weeks at the full 3.0 mg dose. This early-response criterion was based on SCALE data showing that non-responders at 16 weeks were unlikely to achieve clinically meaningful weight loss with continued treatment.

European and Adolescent Expansions

The European Medicines Agency (EMA) approved Saxenda on March 23, 2015. In December 2020, the FDA expanded the indication to include adolescents aged 12 to 17 with body weight above 60 kg and an initial BMI corresponding to 30 kg/m² or greater for adults. The adolescent approval was supported by a 56-week trial (N=251) showing a BMI reduction of 4.64% with liraglutide versus a 1.56% increase with placebo [11].

How Saxenda Works: Mechanism at the Molecular Level

Liraglutide 3.0 mg activates the GLP-1 receptor, a G-protein-coupled receptor expressed in the pancreatic islets, gastrointestinal tract, heart, kidneys, and (most relevant to weight management) the hypothalamus and brainstem.

Central Appetite Regulation

GLP-1 receptors on neurons in the arcuate nucleus and paraventricular nucleus of the hypothalamus mediate satiety signaling. Liraglutide activates pro-opiomelanocortin (POMC) neurons (which suppress appetite) and inhibits neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons (which stimulate hunger). Functional MRI studies have shown that liraglutide reduces activation in brain reward centers in response to food images, suggesting both homeostatic and hedonic appetite pathways are affected [12].

Peripheral Effects on Gastric Motility

Liraglutide slows gastric emptying by 10 to 15%, contributing to post-meal fullness and reduced caloric intake. This effect is most pronounced during the initial weeks of treatment and partially attenuates over time, a phenomenon called tachyphylaxis. The weight loss trajectory in SCALE trials continued well beyond the period of maximal gastric slowing, confirming that central appetite suppression is the primary driver of sustained efficacy [13].

Pancreatic and Glycemic Actions

Even at the 3.0 mg obesity dose, liraglutide preserves its glucose-dependent insulinotropic action: it stimulates insulin release and suppresses glucagon only when blood glucose is elevated, which minimizes hypoglycemia risk. In SCALE Obesity and Prediabetes, the rate of confirmed hypoglycemia in the liraglutide group was 1.3% versus 1.0% for placebo among participants without diabetes [6].

From Saxenda to Semaglutide: The GLP-1 Succession

Saxenda was a first-mover in the GLP-1 weight-loss class, but Novo Nordisk's own pipeline soon produced a successor. Semaglutide 2.4 mg (Wegovy), approved for chronic weight management in June 2021, demonstrated 14.9% mean weight loss at 68 weeks in the STEP 1 trial (N=1,961) [14]. Dr. Robert Kushner, an obesity medicine specialist at Northwestern University and STEP trial investigator, noted: "The magnitude of weight loss with semaglutide 2.4 mg moved pharmacotherapy closer to the efficacy thresholds that we previously associated only with bariatric surgery."

Why Saxenda Still Matters

Despite Wegovy's superior efficacy numbers, Saxenda retains clinical relevance for several reasons. It carries the adolescent indication (ages 12 to 17) that Wegovy later received as well. Some patients who experience intolerable nausea on semaglutide tolerate liraglutide's shorter half-life and daily dosing, which allows more granular dose titration. Supply disruptions of semaglutide products in 2022 and 2023 further sustained demand for liraglutide prescriptions.

The Broader GLP-1 Timeline

Liraglutide's trajectory established the development blueprint that every subsequent GLP-1 weight-loss drug has followed: identify a weight signal in diabetes data, run a dedicated obesity phase 3 program, and pursue a separate obesity-indication approval. Tirzepatide (Zepbound), survodutide, and retatrutide have all moved through this same regulatory arc, each citing the SCALE program as a precedent in their clinical development plans.

Safety Profile and Post-Marketing Surveillance

The SCALE trials identified gastrointestinal events as the most common adverse effects. Nausea occurred in 39.3% of liraglutide-treated patients versus 14.7% on placebo. Vomiting (15.7% vs. 3.9%) and diarrhea (20.9% vs. 9.9%) followed [6]. Most GI symptoms were transient, peaking during the dose-titration phase and subsiding by week 8 to 12.

Pancreatitis and Thyroid Concerns

The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent carcinogenicity studies. In rats, liraglutide produced thyroid C-cell tumors at clinically relevant exposures. Human relevance remains uncertain: the density of GLP-1 receptors on human thyroid C-cells is far lower than in rodents. Across the SCALE program, no medullary thyroid carcinoma cases were reported. Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [10].

Acute pancreatitis was reported in 0.4% of liraglutide-treated patients versus 0.1% on placebo across SCALE. Post-marketing pharmacovigilance through 2024 has not identified a statistically significant increase in pancreatic cancer risk [15].

Cardiovascular Outcomes

The LEADER trial (N=9,340), conducted for the diabetes indication at lower liraglutide doses, demonstrated a 13% relative risk reduction in major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) with liraglutide versus placebo (HR 0.87; 95% CI 0.78 to 0.97; P=0.01) [16]. While LEADER used the 1.8 mg dose, the cardiovascular signal contributed to the broader safety narrative supporting GLP-1 receptor agonist use in patients with obesity and cardiometabolic risk.

The Commercial and Public Health Impact

Saxenda reached peak annual global sales of approximately $1.7 billion in 2022 before semaglutide products began absorbing market share. The drug treated over 1 million patients worldwide between its 2014 approval and 2023. Its commercial trajectory proved a critical business case: it demonstrated that payers, who had historically refused to cover anti-obesity medications, could be persuaded to reimburse GLP-1 therapies when supported by rigorous outcomes data.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity listed liraglutide 3.0 mg among recommended agents, stating: "We suggest that clinicians use one or more of the available medications (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, or liraglutide 3.0 mg) to support lifestyle modification in patients with BMI ≥30 or BMI ≥27 with comorbidities" [17].